Jeremy Chen

Jeremy Chen has a diverse background in scientific research, with a focus on cancer therapeutics and immunology. Jeremy currently works as a Senior Scientist at ArsenalBio since June 2021. Prior to this, they worked at Merck from December 2016 to May 2021 as a Scientist, where they conducted in vivo studies on cancer targeting therapeutics and resistance to anti-PD1 therapy. Jeremy also supported laboratory operations and performed pilot studies on dysregulated metabolism in mouse tumor cell lines. Before Merck, Jeremy worked at City of Hope from September 2014 to November 2016 as a Research Associate II, investigating the causes and potential treatments for aggressive Pancreatic Ductal Adenocarcinoma (PDAC). Jeremy researched Salmonella Typhimurium therapy as a delivery vector for a plasmid encoding a small hairpin RNA (shRNA) to target immunosuppressive molecules and optimized shRNA sequences for silencing PDAC genes. Additionally, they worked at Cedars-Sinai Medical Center from July 2011 to September 2014 as a Research Associate II, studying the pathogenesis of Inflammatory Bowel Disease (IBD) using in vivo mouse models. Jeremy researched the role of autophagy in the clearance of pathogens from the gut and investigated the effects of TL1A overexpression on T-cell dependent ileitis and fibrosis. Overall, Jeremy Chen has extensive experience in scientific research and has contributed to various areas of cancer therapeutics and immunology.

Jeremy Chen attended UC Irvine from 2006 to 2010, where they earned a Bachelor of Science (B.S.) degree in Biology, General.